EYPT

SEC source: 0001562180-24-000391 · primarydocument.xml · derivative · entry 1

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,014

Underlying: Common Stock · 25,014 shares

Expires 2034-01-04

SEC source: 0001562180-24-000403 · primarydocument.xml · derivative · entry 4

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2034-01-04

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000403 · primarydocument.xml · derivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2034-01-05

F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.

SEC source: 0001562180-24-000401 · primarydocument.xml · derivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,014

Underlying: Common Stock · 25,014 shares

Expires 2034-01-04

SEC source: 0001562180-24-000400 · primarydocument.xml · derivative · entry 4

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2034-01-04

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000400 · primarydocument.xml · derivative · entry 3

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2034-01-05

F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.

SEC source: 0001562180-24-000398 · primarydocument.xml · derivative · entry 4

Duker Jay S. · CIK 0001630864 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2034-01-04

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000398 · primarydocument.xml · derivative · entry 3

Duker Jay S. · CIK 0001630864 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-01-05

F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.

SEC source: 0001562180-24-000394 · primarydocument.xml · derivative · entry 1

Duty Stuart · CIK 0001970274 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,014

Underlying: Common Stock · 25,014 shares

Expires 2034-01-04

SEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 6

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 110,000

Underlying: Common Stock · 35,000 shares

Expires 2032-02-09

F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023.

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 35,000 shares

Expires 2032-02-09

F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023.

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

SEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 70,126

Underlying: Common Stock · 10,906 shares

Expires 2030-02-28

F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,674

Underlying: Common Stock · 10,906 shares

Expires 2030-02-28

F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

SEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 151,370

Underlying: Common Stock · 31,164 shares

Expires 2031-02-09

F1 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,330

Underlying: Common Stock · 31,164 shares

Expires 2031-02-09

F1 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 8

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 110,000

Underlying: Common Stock · 35,000 shares

Expires 2032-02-09

F8 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023.

F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 7

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 35,000 shares

Expires 2032-02-09

F8 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023.

F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 6

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 70,126

Underlying: Common Stock · 10,906 shares

Expires 2030-02-28

F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,674

Underlying: Common Stock · 10,906 shares

Expires 2030-02-28

F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 151,370

Underlying: Common Stock · 31,164 shares

Expires 2031-02-09

F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,330

Underlying: Common Stock · 31,164 shares

Expires 2031-02-09

F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

SEC source: 0001562180-24-000133 · primarydocument.xml · nonDerivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 52,208

F1 · date: This transaction was inadvertently left off of the original Form 4 filing on January 2, 2024.

F2 · kind: On December 28, 2023, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000133 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,351

F1 · date: This transaction was inadvertently left off of the original Form 4 filing on January 2, 2024.

F2 · kind: On December 28, 2023, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.

SEC source: 0001562180-23-008415 · primarydocument.xml · derivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,917

Underlying: Common Stock · 1,458 shares

Expires 2032-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-23-008415 · primarydocument.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,707

SEC source: 0001562180-23-008415 · primarydocument.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000929638-23-003419 · form4.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 6,038,235

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001562180-23-008222 · primarydocument.xml · nonDerivative · entry 2

Liu Ye · CIK 0001840407 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Ocumension Therapeutics

Disclosed balance after: 2,010,721

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.49. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001840315-23-000007 · primary_doc.xml · nonDerivative · entry 2

Ocumension Therapeutics · CIK 0001840315 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,010,721

SEC source: 0001562180-23-008222 · primarydocument.xml · nonDerivative · entry 1

Liu Ye · CIK 0001840407 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Ocumension Therapeutics

Disclosed balance after: 2,276,963

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $20.38. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001840315-23-000007 · primary_doc.xml · nonDerivative · entry 1

Ocumension Therapeutics · CIK 0001840315 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,276,963

SEC source: 0001562180-23-008170 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,559

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $22.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-008172 · primarydocument.xml · derivative · entry 3

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 45,000 shares

Expires 2032-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-23-008172 · primarydocument.xml · nonDerivative · entry 2

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,343

SEC source: 0001562180-23-008172 · primarydocument.xml · nonDerivative · entry 1

Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,343

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

SEC source: 0001562180-23-008171 · primarydocument.xml · derivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,375

Underlying: Common Stock · 30,625 shares

Expires 2032-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-23-008171 · primarydocument.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,707

SEC source: 0001562180-23-008171 · primarydocument.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 17

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,450,000

F18 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $34.30 to $34.75 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 16

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,441,740

F17 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $33.30 to $34.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 15

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,421,874

F16 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $32.30 to $33.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 14

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,380,050

F15 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $31.30 to $32.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 13

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,293,337

F14 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $30.30 to $31.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 12

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,277,755

F13 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $29.30 to $30.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 11

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,259,154

F12 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $28.30 to $29.28 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 10

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,250,986

F11 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $27.30 to $28.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 9

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,223,561

F10 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $26.30 to $27.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 8

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,170,452

F9 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $25.30 to $26.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 7

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,105,366

F8 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $24.30 to $25.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-23-003383 · form4.xml · nonDerivative · entry 6

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,065,467

F7 · price: Represents the weighted average sale price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $23.30 to $24.29 per share.

F19 · price: The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.